Jack Allen
Stock Analyst at Baird
(1.52)
# 3,469
Out of 5,043 analysts
41
Total ratings
41.18%
Success rate
-8.16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VOR Vor Biopharma | Upgrades: Outperform | $20 → $64 | $27.19 | +135.38% | 5 | Oct 15, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Outperform | $7 → $12 | $4.75 | +152.63% | 5 | Oct 2, 2025 | |
| FATE Fate Therapeutics | Maintains: Neutral | $5 → $4 | $1.65 | +142.42% | 2 | May 14, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $12 → $9 | $1.20 | +650.00% | 3 | May 14, 2025 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $80 → $40 | $14.98 | +167.11% | 2 | Nov 15, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $77 → $106 | $84.68 | +25.18% | 5 | Nov 6, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $24 → $18 | $25.60 | -29.69% | 2 | Oct 25, 2024 | |
| TIL Instil Bio | Reiterates: Outperform | $180 | $19.40 | +827.84% | 9 | Sep 16, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Outperform | $8 | $2.00 | +300.00% | 1 | Jun 13, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $46 → $52 | $67.61 | -23.09% | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $84 | $33.18 | +153.16% | 1 | Oct 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $1.70 | +194.12% | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.48 | - | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $6 → $9 | $4.65 | +93.55% | 1 | Oct 7, 2021 |
Vor Biopharma
Oct 15, 2025
Upgrades: Outperform
Price Target: $20 → $64
Current: $27.19
Upside: +135.38%
Taysha Gene Therapies
Oct 2, 2025
Maintains: Outperform
Price Target: $7 → $12
Current: $4.75
Upside: +152.63%
Fate Therapeutics
May 14, 2025
Maintains: Neutral
Price Target: $5 → $4
Current: $1.65
Upside: +142.42%
Allogene Therapeutics
May 14, 2025
Maintains: Outperform
Price Target: $12 → $9
Current: $1.20
Upside: +650.00%
MiNK Therapeutics
Nov 15, 2024
Maintains: Outperform
Price Target: $80 → $40
Current: $14.98
Upside: +167.11%
Arcellx
Nov 6, 2024
Maintains: Outperform
Price Target: $77 → $106
Current: $84.68
Upside: +25.18%
Intellia Therapeutics
Oct 25, 2024
Maintains: Neutral
Price Target: $24 → $18
Current: $25.60
Upside: -29.69%
Instil Bio
Sep 16, 2024
Reiterates: Outperform
Price Target: $180
Current: $19.40
Upside: +827.84%
Mereo BioPharma Group
Jun 13, 2024
Initiates: Outperform
Price Target: $8
Current: $2.00
Upside: +300.00%
CRISPR Therapeutics AG
May 9, 2024
Maintains: Neutral
Price Target: $46 → $52
Current: $67.61
Upside: -23.09%
Oct 31, 2023
Initiates: Outperform
Price Target: $84
Current: $33.18
Upside: +153.16%
Nov 2, 2022
Initiates: Outperform
Price Target: $5
Current: $1.70
Upside: +194.12%
May 18, 2022
Upgrades: Outperform
Price Target: n/a
Current: $3.48
Upside: -
Oct 7, 2021
Upgrades: Outperform
Price Target: $6 → $9
Current: $4.65
Upside: +93.55%